Royalty Pharma plc is a key player in the biopharmaceutical industry, specializing in the acquisition of biopharmaceutical royalties and funding innovation. With a focus on collaboration, the company works alongside academic institutions, research hospitals, and companies of various sizes to support the development of new therapies. Its diverse portfolio includes royalties on over 35 commercial products and 14 products in development, covering areas like rare diseases, cancer, and diabetes. Founded in 1996, Royalty Pharma is headquartered in New York, New York, marking its influence in the healthcare sector.